Blood typing is a method of classifying blood into different blood groups depending on the presence of different antigens on the surface of red blood cells (RBCs). Understanding the different blood groups is vital in preventing complications from blood transfusion.
In this article, we will explore the most common blood grouping systems, blood transfusions, associated investigations, and clinical correlations.
ABO Grouping System
Erythrocytes (RBCs) have multiple glycoprotein antigens attached to their cell surface. The most important are ABO antigens, which determine a person’s ABO blood group. An individual inherits one ABO allele from each parent, with A and B alleles being codominant and producing the A and B antigens respectively.
- Group A – have antigen A attached to the erythrocyte cell surface
- Group B – have antigen B attached to the erythrocyte cell surface
- Group AB – have both antigen A and B attached to the erythrocyte cell surface
- Group O – have neither antigen attached to the erythrocyte cell surface
Each person also has ABO antibodies in their plasma, which will recognise and attack RBCs expressing foreign antigens. These antibodies develop over the first months and years of life. This is crucial in blood transfusion as giving someone an incompatible blood group can be potentially fatal. The A and B antibodies are predominantly IgM.
- Group A – have anti-B antibodies
- Group B – have anti-A antibodies
- Group AB – have neither antibody
- Group O – have both anti-A and anti-B antibodies
Rhesus Grouping System
The second most important blood grouping system is based on Rhesus (Rh) antigens. There are many different Rh antigens but only 5 are clinically significant: D, C, c, E, and e.
Rh D is the most immunogenic (i.e. likely to produce an immune response) and therefore the most likely to precipitate a transfusion reaction. The presence or absence of Rh D antigen on the erythrocyte cell surface determines whether the person has Rh positive (Rh+) or Rh negative (Rh-) blood groups.
- Rh positive: have the Rh D antigen and can receive both Rh+ and Rh- blood
- Rh negative: lack the Rh D antigen and should only receive Rh- blood
Rh negativity is generally more prevalent in Caucasian populations (15%), than Afro-Caribbean (8%) and Asian (1%) populations but prevalence varies in different parts of the world.
Anti-D antibody is usually absent in Rh- patients (until they have been exposed to Rh+ erythrocytes). Rh- patients should not be transfused with Rh+ blood as this can cause them to develop anti-D antibodies. This may cause transfusion reactions in the future.
Alongside ABO and Rh blood groups, there are many other grouping systems based on other antigens. These antigens can also, more rarely, cause transfusion reactions.
Clinical Relevance – Blood Transfusion
A person should not receive blood products containing antigens for which they have the corresponding antibodies. Transfusing an incompatible blood type will precipitate a potentially fatal transfusion reaction as the recipient’s ABO antibodies attack the donor’s antigen (seen as foreign). Patients having blood transfusions need to be frequently monitored, particularly at the start of each unit.
People with blood type O- are universal donors – they can donate their blood to anyone. This is because their RBCs have no A, B, or RhD antigens which the recipient’s immune system could attack.
People with blood type AB+ are universal recipients – they can receive blood from anyone. This is because their plasma does not contain anti-A, anti-B, or anti-D antibodies, so they will usually not mount an immune response to the donor blood.
Clinical Relevance – Haemolytic Disease of the Newborn (HDN)
Anti-D antibodies cause the most severe type of HDN.
Exposure of a Rh- person to the Rh D antigen causes Rh D sensitisation. For instance, during a first pregnancy if the foetus is Rh+. The presence of Rh D antigens in the maternal circulation stimulates the production of anti-D antibodies.
Maternal anti-D antibodies recognise and destroy foetal Rh+ RBCs. Upon first exposure, the antibodies are IgM, which cannot cross the placenta and will not cause issues in the first pregnancy. However, future Rh+ pregnancies will result in the production of large amounts of IgG anti-D which can cross the placenta and cause haemolysis.
Thankfully the administration of anti-D Ig prophylaxis to unsensitised Rh- mothers has significantly reduced the incidence of HDN caused by anti-D antibodies. The prophylaxis works by destroying foetal RBCs that leak into the maternal circulation, reducing the chance of Rh D sensitisation.
Clinical Relevance – Blood typing and Cross-matching
Blood typing (also known as a “group and save”) followed by cross-matching helps avoid transfusion of incompatible blood types.
ABO typing tests the patient’s blood for the presence of A/B antigens, and A/B antibodies. This is followed by Rh typing. The lab will also screen the patient’s blood for atypical antibodies.
Cross-matching involves mixing the donor’s blood with the recipient’s blood to detect any immune reaction.
Clinical Relevance – Antiglobulin Testing (Coombs’ Test)
Direct Antiglobulin Testing (DAT) detects whether a patient’s RBCs have antibodies directly attached to them. Coombs’ reagent binds to specific immunoglobulins on the RBCs. It is added to the patient’s blood. A positive test results in the RBCs agglutinating (clumping together).
A positive DAT indicates that haemolysis has an immune aetiology, causes include autoimmune haemolytic anaemia, haemolytic transfusion reactions, and HDN.
Indirect Antiglobulin Testing (IAT) detects antibodies present in the patient’s plasma. This can be used in cross-matching or to detect maternal anti-D IgG. Donor’s RBCs and Coombs’ reagent is combined with the patient’s isolated plasma.
Again, the test is positive if agglutination occurs. This indicates the patient has antibodies against the antigens present on the donor’s RBCs.